14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MBIO vs NVO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Novo-Nordisk A/S (NVO) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas NVO carries 35.1/100 (SELL) at $41.60 (12.5x Forward P/E, 50.8% operating margin).
Composite vs. Pillar Nuance: While MBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. NVO 35.1/100 SELL), NVO captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (50.8% vs. 0.0% operating margin) and revenue trajectory (+5.6% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs NVO. Trailing 12-month operating profitability (MBIO 0.0% vs NVO 50.8%) and valuation multiples (MBIO N/M vs NVO 12.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
NVO Moat ProfileHigh-Margin Pricing Power Moat
Global GLP-1 Diabetes & Obesity Biologics Leader
Operates vertically integrated peptide fermentation and auto-injector supply chains serving global diabetes and weight-management markets.
OpEx & R&D Reinvestment32.5% of Rev ($16.7B)
90D Engineering Disclosures0 Published
Investor FAQ MBIO vs NVO Key Questions & Quantitative Answers
As of Nov 16, 2026, Novo-Nordisk A/S (NVO) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas NVO carries 35.1/100 (SELL) at $41.60 (12.5x Forward P/E, 50.8% operating margin). Composite vs. Pillar Nuance: While MBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. NVO 35.1/100 SELL), NVO captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (50.8% vs. 0.0% operating margin) and revenue trajectory (+5.6% vs. +0.0% YoY).
NVO leads the Growth & Scale pillar: MBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NVO at +5.6% YoY revenue growth and -15.8% YoY earnings growth on $51.5B TTM revenue (83.3% gross margin, 50.8% operating margin). On trailing 12-month operating scale, MBIO generates N/A in USD-normalized revenue versus $51.5B for NVO. In operating R&D and SG&A reinvestment, MBIO deploys N/A (0 90-day corporate R&D disclosures) versus 32.5% of Rev ($16.7B) (0 disclosures) for NVO.
NVO screens cheaper on headline valuation multiples. MBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NVO trades at 12.5x Forward P/E, 10.5x Trailing P/E, 4.31x PEG, and 3.8x EV/Revenue (13.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBIO (-43.1% ROE) versus NVO (58.4% ROE) capital efficiency.
In options market volatility and institutional positioning, MBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.66β · 86% Vol realized risk). By comparison, NVO carries 36.7% implied volatility (32nd %ile, Balanced (25th–60th %ile)), a 0.87x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.50β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.